Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - Καρκίνωμα, μη μικροκυτταρικός πνεύμονας - Αντινεοπλασματικοί παράγοντες - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - Πολλαπλό μυέλωμα - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.